ORCA Therapeutics
Phase 1/2ORCA aims to significantly improve the lives of prostate cancer patients by developing safe and highly potent oncolytic virus immunotherapies.
Founded
2016
Focus
Small Molecules
About
ORCA aims to significantly improve the lives of prostate cancer patients by developing safe and highly potent oncolytic virus immunotherapies.
Funding History
2Total raised: $12.5M
Series A$10MYsios CapitalMar 15, 2022
Seed$2.5MBioGeneration VenturesOct 15, 2020
Company Info
TypePrivate
Founded2016
LocationLeiden, Netherlands
StagePhase 1/2
Contact
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile